Antibacterial Drugs: World Industry and Market Prospects 2015-2025

LONDON, June 8, 2015 /PRNewswire/ --

Antibacterial medicines - your guide to business trends, R&D and future revenues 

What's the future of treatments for human bacterial infections? For those antibiotics you get new revenue predictions, also exploring research and development. Those drugs hold high selling potentials. There you assess results, progress, therapies and opportunities.

Visiongain's new report forecasts those revenues to 2025 at overall world market, submarket, product and national level. It explains what the future holds. There stay ahead in data on treating microbial diseases, discovering prospects to benefit your work and authority.

Read on to explore those antimicrobial medicines and their sellers, seeing how high that industry's sales can go.

Forecasts to 2025 and other analyses explain and predict the vast antibacterials market 

Why miss business data you need? Why struggle to find it or fall behind? Instead our investigation shows sales results, market shares, multilevel revenue forecasts and commercial trends to help your decisions and influence.

In particular you explore product development, seeing agents shaping the future and assessing their potentials. That study gives 123 tables, 97 charts and three research interviews with authorities.

And the following sections show how that new survey helps your research, analyses and decisions, helping you stay ahead in knowledge.

Sales predictions for the world antibiotics market and submarkets - see what's possible 

What's that biomedical industry's potential? What're the secrets of its progress? Discover in our report overall world revenue forecasting to 2025 for those bacteria-treating agents.

Also find individual revenue predictions to 2025 for six therapeutic submarkets at world level:
• Cephalosporins
• Penicillins
• Fluoroquinolones
• Macrolides
• Carbapenems
• Other drug-based therapies for bacterial infections.

To see a report overview please email Sara Peerun on [email protected]

There you explore prospects from 2015, discovering potentials of novel agents and generic drugs.

That way find where the money lies. Hear how companies, patients and healthcare providers can benefit, assessing the most important product classes and companies.

That study also predicts and discusses leading antibiotics' revenue potentials.

Predictions for leading and expected products - what future demand and sales?
How will individual drugs perform to 2025 at world level? Our survey forecasts revenues of 43 agents - original marketed brands, generic compounds and emerging medicines.

You assess top products, including these, seeing what sales they can achieve:
• Zyvox
• Cubicin
• Augmentin
• Zosyn/Tazocin
• Avelox
• Invanz
• Generic amoxcillin
• Tedizolid.

There find medicines and years with highest predicted revenues. You also examine competitors. So discover what's happening, understanding, challenges, trends and commercial outlooks, including effects of product obsolescence and rising competition.

For that overall market, the new analysis also shows you geographical revenue predictions.

National markets - high needs worldwide for treating infections give rising antibiotic demand 

In developed and developing countries, many opportunities for producers and sellers of bactericidal medicines will occur from 2015. See where and how, finding what's possible.

Our work shows you individual revenue forecasts to 2025 for 12 national markets:
• United States (US)
• Germany, France, UK, Italy and Spain (EU5 countries) and the overall European Union
• China, India, Brazil and Russia (BRIC nations)
• South Korea
• Japan

For healing people and saving lives, you explore progress, needs and potentials. Find how pharma companies can satisfy those demands for treating bacterial infections. There you also assess financial potentials from developing, manufacturing and marketing antibiotics.

And what events change that large, vital medical industry? Our survey shows you, discussing trends, challenges and opportunities.

To see a report overview please email Sara Peerun on [email protected]

Market forces and issues - what affects developers, producers and sellers of antibacterials? 

That updated report explains issues and events affecting that industry and market from 2015, including these influences:
• Antibacterial drug consumption at national level - demand in developed and developing regions and countries
• Incidence of pneumonia, community acquired urinary tract infections, bacterial skin disorders and upper respiratory tract infections in leading countries
• Generic competition for leading brands - effects of patent expiries and follow on therapies
• Prescription control to combat drug-resistant strains and threats from methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus (VRE)
• Drug discovery and development - push and pull incentives, inc. public-private collaborations and other alliances.

And you explore these forces on that industry, among others:
• R&D pipelines for small-molecule and biological antibacterials (biologics), including monoclonal antibodies (mAbs) and inhaled formulations
• Oxazolidinones and other drug classes to stimulate the market
• Treating and preventing hospital-acquired infections (HAIs)
• Potential for smaller pharma companies to succeed, esp. with partnerships
• Guidelines from regulatory bodies and other healthcare policies - effects of changes.

You discover what the future holds. There explore political, economic, social and technological questions. See, too, how R&D lets companies benefit patients and keeps that industry progressing, including overcoming bacterial resistance and serving emerging needs.

See, then, what's possible from 2015 for that industry, its technology and participants.

Analysis of top companies and potential for market growth - what revenue possible? 

So what happens next? Our study predicts that world market will reach $43.2bn in 2019, with revenue expansion from 2015 to 2025.

In that study discover what drives that commercial expansion. And see what's possible. In particular you explore activities and potentials of these companies:
• Pfizer
• GlaxoSmithKline
• Novartis
• Merck & Co.
• Cubist Pharmaceuticals
• Bayer.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from bacteria-treating drugs. See what the future holds there, finding how you can gain.

Ways Antibacterial Drugs: World Industry and Market Prospects 2015-2025  helps

In particular, visiongain's investigation gives this information to help your work:
• Revenues for antibacterial drugs to 2025 at world level, for 6 submarkets and 43 medicines - assess outlooks for development, production, marketing and sales

• Forecasts to 2025 for 12 national markets in the Americas, Europe and Asia - investigate developed and developing countries for potential revenues
• Prospects for established competitors, rising companies and new entrants - explore portfolios, technologies, results, strategies, R&D and outlooks for success
• Discussions of research and development - see progress in that industry, finding technological, clinical and commercial outlooks and opportunities
• Opinions from companies and other organisations - discover, through three interviews, views to help you stay ahead in knowledge

• Analysis of what stimulates and restrains that antimicrobial drugs market - assess challenges and strengths, helping you compete and gain advantages.

That report, by our UK-based analysts, gives knowledge to benefit your research, planning, decisions and proposals. There get data leading companies depend on again and again.

Knowledge found nowhere else, helping your work, authority and reputation for insight
Our study gives independent data. There receive competitive intelligence found only in our work, finding where progress, potential and money lie. You explore what the future holds.

With that original research and analysis you're less likely to fall behind in information or miss opportunity. Through your choice now, find how you could save time and effort. That way, benefit your research, analysis and reputation for insight.

The new report shows potentials of medicines for treating human bacterial diseases. There explore trends and R&D, also discovering sales forecasts. So avoid missing out in technological and commercial knowledge. Please get that study here now.

To see a report overview please email Sara Peerun on [email protected]

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)20-7336-6100

Or click on http://goo.gl/ZD8dvb

Companies and Other Organisations Mentioned in This Report 

Abbott Laboratories

AbbVie

Achaogen

Actavis

Actelion

Affinium Pharmaceutical

AiCuris GmbH & Co. KG

Alcon

Alkem Laboratories

Allergan

Allied Pharma

ANVISA

Apotex

APP Pharmaceuticals

Aptalis Pharma

Aquapharm Biodiscovery

Aradigm

Aridis Pharmaceuticals

Ascend Therapeutics

Astellas Pharma

AstraZeneca

Aurobindo Pharma

Barr Pharmaceuticals

Basilea Pharmaceuticals

Bayer Laboratories

Biomax Biotechnics

Bristol-Myers Squibb

Cadila Healthcare

Calixa Therapeutics

Cardeas Pharma

Cellceutix

Cempra Pharmaceuticals

Cipla

Claris Lifesciences

Cornerstone Biopharma

Cornerstone Therapeutics

Corona Remedies

Critical Therapeutics

Cubist Pharmaceuticals

Daiichi Sankyo

Dainippon Sumitomo

Discuva

Dr. Reddy's Laboratories

Duke University

Durata Therapeutics

Eli Lilly

European Medicines Agency (EMA)

Emcure Pharmaceuticals

Eros Pharma

Food and Drug Administration (FDA)

Forest Laboratories

Furiex Pharmaceuticals

Gate Pharma

Gilead Sciences

Glenmark

GlycoVaxyn

GlaxoSmithKline (GSK)

Hetero

Hi Tech Pharma

Hikma Farmaceutica

Hospira

Insmed

Intercell

Itochu Chemical Frontier

Janssen Pharmaceuticals

Johnson & Johnson

KaloBios

Kenta Biotech

Kuhnil Pharm

Lupin

Macleod Pharmaceuticals

Medicis

MedImmune

Meiji

Melinta Therapeutics

Merck & Co.

Merlion Pharmaceuticals

Ministry of Health, Labour and Welfare (MHLW)

Michigan State University

Microlabs

MicuRx Pharmaceuticals

Mpex Pharmaceuticals

Mylan

Nabriva Therapeutics

Nalneva

Neiss Labs

Nektar Therapeutics

National Institute for Health and Clinical Excellence (NICE)

National Institutes of Health (NIH)

Novacta Biosystems

Novartis

Novexel

Optimer Biotechnology

Orchid Chemicals

Orchid Healthcare

Ortho-McNeil

Paratek Pharmaceuticals

Peninsula Pharmaceuticals

Pfizer

Pharmacia

Phico Therapeutics

Piramal Healthcare

Plenus Pharmaceuticals

Pliva

Polyphor

Procarta Biosystems

Procter & Gamble Pharmaceuticals

Ranbaxy

Redx Pharma

Roche

Roxane

R-Pharma

Sagent Pharmaceuticals

Sandoz

Sanofi

Savara Pharmaceuticals

Sawai Pharmaceutical

Schering Plough

Seika Pharma

Sequella

Shanghai MengKe Pharmaceuticals

Shionogi

Shire

Sidmak Labs

Solitaire Pharmacia

Specialised Therapeutics Australia

Sunovion Pharma

TaiGen Biotechnology

Taisho Toyama

Takeda

TAP Holdings

Targanta Therapeutics

Tetraphase Pharmaceuticals

Teva Pharmaceutical Industries

The Medicines Company

Theravance

Torrent Pharmaceuticals

Trius Therapeutics

TTY Biopharma

Unichem Laboratories

University of Connecticut

Valeant Pharmaceuticals

Vansen Pharma

ViroPharma

Warner Chilcott

Watson

World Health Organization (WHO)

Wockhardt

Zhejiang Medicine Company

Zuellig Pharma

Zydus Pharmaceuticals

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)20-7336-6100

Or click on http://goo.gl/ZD8dvb

SOURCE Visiongain